International Congress of Parkinson’s Disease and Movement Disorders® 2026

🇰🇷 Honored to announce that Dr. Manuel Blanc, Co-founder & CEO, will present our latest research on LYS241, Lys Therapeutics’ first-in-class monoclonal antibody, during an 𝗼𝗿𝗮𝗹 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 at the 𝟮𝟬𝟮𝟲 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗠𝗼𝘃𝗲𝗺𝗲𝗻𝘁 𝗗𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 in Seoul, organized by the International Parkinson and Movement Disorder Society.

🎯 “𝘼 𝙉𝙤𝙫𝙚𝙡 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘 𝙏𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝙩𝙋𝘼-𝙉𝙈𝘿𝘼𝙧 𝙄𝙣𝙩𝙚𝙧𝙖𝙘𝙩𝙞𝙤𝙣 𝙛𝙤𝙧 𝙈𝙪𝙡𝙩𝙞𝙥𝙡𝙚 𝙎𝙮𝙨𝙩𝙚𝙢 𝘼𝙩𝙧𝙤𝙥𝙝𝙮”

Our presentation will highlight new preclinical findings supporting the potential of LYS241 as a 𝗱𝗶𝘀𝗲𝗮𝘀𝗲-𝗺𝗼𝗱𝗶𝗳𝘆𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗳𝗼𝗿 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗦𝘆𝘀𝘁𝗲𝗺 𝗔𝘁𝗿𝗼𝗽𝗵𝘆, a devastating neurodegenerative disease with no approved disease-modifying treatment.

In particular, we look forward to sharing our latest data on the 𝗽𝗿𝗲𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘀𝘁𝗿𝗶𝗮𝘁𝗮𝗹 𝗺𝗲𝗱𝗶𝘂𝗺 𝘀𝗽𝗶𝗻𝘆 𝗻𝗲𝘂𝗿𝗼𝗻𝘀 𝗮𝗻𝗱 𝗳𝘂𝗹𝗹 𝗿𝗲𝘀𝘁𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝗼𝘁𝗼𝗿 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝘁𝗼 𝗹𝗲𝘃𝗲𝗹𝘀 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝗯𝗹𝗲 𝘁𝗼 𝗵𝗲𝗮𝗹𝘁𝗵𝘆 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝘀, further strengthening the therapeutic rationale for targeting the pathological tPA–NMDAr interaction in #MSA and other #synucleinopathies.

📍 Join us in Korea!

📅 Sunday, October 4, 2026
🕤 9:30–10:30 AM (KST)
📌 E-Poster Station 4, Hall D
🎤 Oral Presentation #237

#MDSCongress #MSA #MultipleSystemAtrophy #LYS241 #LysTherapeutics #Neuroscience #Neurodegeneration #DrugDevelopment